Table 1. Baseline clinicopathologic characteristics of patients.
| Characteristics | Neoadjuvant immunotherapy (n=25) | Neoadjuvant chemotherapy (n=82) | P value |
|---|---|---|---|
| Age, years | 62.9 (60.4–65.4) | 59.1 (57.2–60.9) | 0.056 |
| Male | 16 (64.0) | 56 (68.3) | 0.689 |
| Smoking history | 15 (60.0) | 48 (58.5) | 0.896 |
| FEV1, L | 2.8 (2.5–3.0) | 2.6 (2.5–2.7) | 0.234 |
| ECOG PS | 0.225 | ||
| 0 | 7 (28.0) | 34 (41.5) | |
| 1 | 18 (72.0) | 48 (58.5) | |
| BMI, kg/m2 | 24 (22.3–25.7) | 25.2 (24.5–25.9) | 0.194 |
| Histology | 0.345 | ||
| Adenocarcinoma | 13 (54.2) | 54 (70.1) | |
| Squamous cell carcinoma | 8 (33.3) | 17 (22.1) | |
| Others | 3 (12.5) | 6 (7.8) | |
| Tumor size, mm | 35.5 (32.0–39.0) | 34.7 (32.4–37.0) | 0.456 |
| Clinical T stage | 0.066 | ||
| T1 | 4 (16.0) | 29 (35.4) | |
| T2 | 21 (84.0) | 53 (64.6) |
Data are presented as no. (%) or mean (95% confidence interval). FEV1, forced expiratory volume during the first second; BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group Performance Status.